<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9429">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05698017</url>
  </required_header>
  <id_info>
    <org_study_id>Cyt MSA hOMSC300</org_study_id>
    <nct_id>NCT05698017</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early- to Moderate Stage MSA</brief_title>
  <official_title>Phase 1/2a Randomized Controlled Study for Treatment of Early- to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytora Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytora Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this phase 1/2a study is to assess the safety and efficacy of intrathecal&#xD;
      administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from&#xD;
      early to moderate stage Multiple System Atrophy (MSA) .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2022</start_date>
  <completion_date type="Anticipated">February 19, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be allocated to one of the following arms:&#xD;
Low dose single intrathecal (IT) administration of hOMSC300&#xD;
High dose single intrathecal (IT) administration of hOMSC300&#xD;
Sham procedure (control)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related SAEs per dose group</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related adverse events per dose group</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically significant motor and behavioral change from baseline</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Multiple System Atrophy</condition>
  <condition>MSA - Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>Low dose hOMSC300</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single IT administration of low dose hOMSC300</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose hOMSC300</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single IT administration of high dose hOMSC300</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Procedure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lumbar puncture only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hOMSC300</intervention_name>
    <description>Human Oral Mucosa Stem Cells</description>
    <arm_group_label>High dose hOMSC300</arm_group_label>
    <arm_group_label>Low dose hOMSC300</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>Lumbar Puncture Only</description>
    <arm_group_label>Sham Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient was diagnosed with probable MSA-C (cerebellar) or MSA-P (parkinsonian) variant&#xD;
             within 60 months of symptom onset (excluding impotence)&#xD;
&#xD;
          -  Subject can ambulate without the assistance of another person, defined as the ability&#xD;
             to take at least 10 steps. Use of assistive devices is allowed&#xD;
&#xD;
          -  Patient cognitive state permits him to sign informed consent, according to the PI's&#xD;
             clinical judgement, and MoCA &gt;= 24&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women and women before menopause&#xD;
&#xD;
          -  Participants with a clinically significant or unstable medical or surgical condition&#xD;
             that, in the opinion of the investigator, might preclude safe completion of the&#xD;
             treatment or affect the treatment outcome.&#xD;
&#xD;
          -  Patients with thrombocytopenia, other bleeding diathesis or taking anticoagulant&#xD;
             therapy (not including Aspirin up to 100mg per day)&#xD;
&#xD;
          -  Patients with known hypersensitivities to Plasmalyte, Gadolinium, Penicillin, and with&#xD;
             general hypersensitivity to antibiotics&#xD;
&#xD;
          -  Patients who fulfill the criteria of Parkinson's Disease&#xD;
&#xD;
          -  History of electroconvulsive therapy&#xD;
&#xD;
          -  History of brain surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center (Ichilov)</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adi Ezra, MHA</last_name>
      <phone>972-52-4266940</phone>
      <email>adil@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Vered Livneh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 16, 2023</study_first_submitted>
  <study_first_submitted_qc>January 24, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 24, 2023</last_update_submitted>
  <last_update_submitted_qc>January 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple system atrophy</keyword>
  <keyword>MSA</keyword>
  <keyword>stem cells</keyword>
  <keyword>intrathecal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

